How standardized pine bark extract becomes metabolites, what is known about eNOS, COX and 5-LOX, and where clinical trials show positive or negative results.
How structural differences between curcumin, DMC, and BDMC affect redox chemistry and IKK/NF-κB signaling; what positive and negative RA trials show, and where evidence of efficacy and safety ends.
DGL reduces glycyrrhizin exposure, but does not eliminate risk. Gastric mucus and secretin physiology explain hypotheses; controlled trials show mixed, formulation-specific results.
How polaprezinc relates to gastric retention, Hsp70 and the intestinal barrier; what aspirin, exercise, H. pylori and mucositis trials actually showed, with elemental zinc calculations and copper risks.
How probiotic yeast affects bacterial toxins, what trials show about antibiotic-associated diarrhea, why current CDI guidance differs, and when fungemia risk rules out use.
How LOLA substrates connect urea synthesis, liver zonation and muscle glutamine metabolism, and what randomized trials actually show about hepatic encephalopathy, recurrence, acute liver failure and safety.
DLinPC chemistry, digestion and remodeling, mitochondria, PLA2, fibrosis, VLDL and bile. How model effects differ from MANPOWER, VA and EXCEL outcomes and clinical liver repair.
Extract composition, stereochemistry, oral and IV exposure, membrane experiments, OATP1B3, rat Pol I/rRNA, redox and fibrosis pathways. Primary liver trials, negative endpoints, interactions and formulation limits.
Cynarin, luteolin, and cynaropicrin chemistry; choleresis and cholekinesis, bile transporters, CYP51A1/HMGCR, and clinical findings. Separating physiology, cellular experiments, and human evidence.
Taurine synthesis and transport, U34 modifications, MTO1/GTPBP3 and TRMU, codon decoding, complex I, MELAS and conflicting aging findings.
From berry composition and lignan stereochemistry to chaperones, mitochondrial glutathione, Nrf2, and neuroendocrine hypotheses: human research, standardization, and drug interactions.
From a bacterial quinone cofactor and cellular mitochondrial biogenesis to cardiac and brain models, small human studies, and toxicological limits.
Monacolin K, HMGCR, and LDLR: fermentation biochemistry, Xuezhikang clinical evidence, muscle risks, CoQ10, citrinin, and current restrictions. Efficacy and safety depend on the particular intervention.
The chemistry of two stilbenes, conjugation and free aglycone, conditional SIRT1 allostery, the indirect PDE–AMPK pathway, clinical markers, and safety boundaries.
Passiflora incarnata flavonoids, chrysin bioavailability, the GABA synapse, and benzoflavones: what experiments and small trials tell us about anxiety and insomnia, how to distinguish preparations, and how to assess safety.
